Journal: Cancers

Article Title: Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures

doi: 10.3390/cancers13195009

Figure Lengend Snippet: TNBC tissues are represented by different patient-specific signaling signatures, majority of which do not include EGFR. ( A ) Fold changes in expression levels of EGFR and pEGFR in TNBC and non-TNBC tumors are shown. Y1068 and Y1173 are EGFR phosphorylation sites; ( B ) Examples for patient-specific sets of active unbalanced processes are shown. Each sample harbors a set of 1–3 active unbalanced processes (PaSSS), represented schematically by a barcode. In each barcode active unbalanced processes are represented by black or gray squares, inactive white. Negative/positive amplitude denotes how the patients are correlated with respect to a particular process. Suggested PaSSS-based therapies appear below each barcode; ( C ) Heterogeneity index of 3 subgroups, represented by a ratio between the number of distinct PaSSSs and the number of samples in each subset, is shown for the TNBC subset of tissues, the entire set (3467 samples from 11 cancer types) and the subset of non-TNBC samples. (Abbreviations: TNBC—Triple Negative Breast Cancer, PaSSS—Patient-specific signaling signature, EGFR—Epidermal Growth Factor Receptor, VEGFR2—Vascular Endothelial Growth Factor Receptor 2, Her2—Human Epidermal growth factor Receptor 2, Src—Proto-oncogene tyrosine-protein kinase Src).

Article Snippet: The following conjugated antibodies were used: anti-p-EGFR (Y1068) (R&D Systems, Minneapolis, MN, USA, cat. no. IC3570G), anti-p-ERK2 (Thr202/Tyr204) (BioLegend, San Diego, CA, USA, cat. No. 675503), anti-p-S6 (Ser235/236) (BioLegend, cat. no. 608605), and anti-GAPDH (Santa Cruz Biotechnology, Dallas, Texas, USA, cat. no. sc-47724AF594).

Techniques: Expressing, Phospho-proteomics

Journal: Biochimica et biophysica acta. Molecular basis of disease

Article Title: Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

doi: 10.1016/j.bbadis.2024.167572

Figure Lengend Snippet: Key resources.

Article Snippet: Mouse IgG1 anti-human CD326 (EpCAM)-conjugated microbeads , Miltenyi Biotec , Cat# 130–061–101 RRID: AB_2832928.

Techniques: Plasmid Preparation, Magnetic Beads, Recombinant, Blocking Assay, Lysis, Protease Inhibitor, Red Blood Cell Lysis, Software, Microscopy, Fluorescence, Imaging

Journal: Cell Reports Medicine

Article Title: Protein/AS01 B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors

doi: 10.1016/j.xcrm.2021.100207

Figure Lengend Snippet:

Article Snippet: Mouse anti-human IgG-BB515. Clone G18-145. , BD , Cat# 564581, RRID: AB_2738854.

Techniques: Recombinant, Staining, Synthesized, Software

Journal: EBioMedicine

Article Title: Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32

doi: 10.1016/j.ebiom.2020.102953

Figure Lengend Snippet: Comparison of preS-specific isotype and IgG subclasses responses in the four groups of patients. Shown are optical density (OD) values ( y -axes) corresponding to preS-specific IgG, IgA, IgM, IgE and IgG subclass (IgG 1 –IgG 4 ) levels in patients immunized with 3, 4 or 5 injections of BM32 or with placebo (see inlay) at baseline (V3), after one (V8) or four (V11) months treatment ( x -axes). Medians (horizontal bars) and significant differences are indicated: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The detection was performed using either biotin-labeled mouse anti-human IgG 1 (BD, Cat. 555869) or biotin-labeled mouse anti-human IgG 4 (BD, Cat. 555882) in dilution 1:1000 mixed with HRP-conjugated streptavidin (BD, Cat. 554066) in dilution 1:2500 and incubated overnight at 4 °C.

Techniques:

Journal: EBioMedicine

Article Title: Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32

doi: 10.1016/j.ebiom.2020.102953

Figure Lengend Snippet: Quantification of IgG 1 and IgG 4 subclass responses in patients treated with placebo or different numbers of BM32 injections. Shown are absolute increases of serum concentrations of IgG 1 and IgG 4 ( y -axes: μg/ml) specific (a) for preS, (b) for peptide A, (c) for peptide B and (d) for peptide C from baseline (V3) to visits 8 and 11 ( x -axes) inpatients immunized with placebo, 3, 4 or 5 injections of BM32. Medians (horizontal bars) and significant differences are indicated: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The detection was performed using either biotin-labeled mouse anti-human IgG 1 (BD, Cat. 555869) or biotin-labeled mouse anti-human IgG 4 (BD, Cat. 555882) in dilution 1:1000 mixed with HRP-conjugated streptavidin (BD, Cat. 554066) in dilution 1:2500 and incubated overnight at 4 °C.

Techniques:

Journal: EBioMedicine

Article Title: Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32

doi: 10.1016/j.ebiom.2020.102953

Figure Lengend Snippet: Kinetics and fine specificities of anti-preS antibody responses in the individual subjects of the placebo group, and the groups having received 3, 4 or 5 injections. The heat maps depict the log 10 of the serum concentrations of preS- or peptide-specific (a) IgG 1 and (b) IgG 4 . Missing values are indicated in gray.

Article Snippet: The detection was performed using either biotin-labeled mouse anti-human IgG 1 (BD, Cat. 555869) or biotin-labeled mouse anti-human IgG 4 (BD, Cat. 555882) in dilution 1:1000 mixed with HRP-conjugated streptavidin (BD, Cat. 554066) in dilution 1:2500 and incubated overnight at 4 °C.

Techniques: